No Data
DiZhe Pharmaceuticals (688192): Original innovation, small molecule innovative drugs advancing globally.
Executive Summary of this report: The company focuses on original innovation, and its core products are moving towards the global market. Shuonitinib and Golixitinib are gradually entering the harvest period, with ample early pipelines and great potential. We give a shareholding rating in the first coverage. Investment highlights: First coverage, giving a shareholding rating.
Express News | Dizhi Pharmaceuticals: Savolitinib has submitted a listing application to the FDA in the USA.
Dizhi Pharmaceuticals-U (688192): Domestic sales volume of Shuwo Tinib exceeded expectations, focusing on overseas declaration progress
1-3Q24 performance exceeded our expectations. The company announced 1-3Q24 performance: revenue of 0.338 billion yuan, a year-on-year growth of 743.97%; net loss attributable to mother of 0.6 billion yuan, corresponding to a loss of 1.35 yuan per share. The first three quarters.
Dizhi Pharmaceuticals (688016): Persist in research and development investment, the commercialization of innovative drugs is about to surge.
Event: On October 31, 2024, Dezh Pharmaceutical released the third quarter report for 2024, with the company achieving revenue of 0.338 billion yuan in the first three quarters of 2024 (+743.97% year-on-year), attributable to the listed company's shares.
Dizhil Medical (688192): Revenue meets expectations, research and development pipeline progressing rapidly.
The company released its Q3 report for 2024: In the first three quarters of 2024, the company achieved revenue of 0.339 billion yuan (+743.97%) and net income attributable to the parent company of -0.559 billion yuan (+32.63%), non-recurring net income
Express News | The social security fund held positions with a market cap of nearly 190 billion yuan at the end of the third quarter.
No Data
No Data